eMedicine Specialties > Hematology > Transfusion Medicine

Intravenous Immunoglobulin

Author: Noah S Scheinfeld, MD, JD, FAAD, Assistant Clinical Professor, Department of Dermatology, Columbia University; Consulting Staff, Department of Dermatology, St Luke's Roosevelt Hospital Center, Beth Israel Medical Center, New York Eye and Ear Infirmary; Private Practice
Coauthor(s): John E Godwin, MD, MS, Professor of Medicine, Chief Division of Hematology/Oncology, Associate Director, Simmons Cooper Cancer Institute, Southern Illinois University School of Medicine
Contributor Information and Disclosures

Updated: Mar 25, 2008

Introduction

Immune globulin products from human plasma were first used in 1952 to treat immune deficiency. Intravenous immunoglobulin (IVIG) contains the pooled immunoglobulin G (IgG) immunoglobulins from the plasma of approximately a thousand or more blood donors.  Initially, immune globulin products were administered by intramuscular injection.

IVIG was initially shown to be effective in autoimmune idiopathic thrombocytopenic purpura (ITP) in 1981.1 IVIGs are sterile, purified IgG products manufactured from pooled human plasma and typically contain more than 95% unmodified IgG, which has intact Fc-dependent effector functions and only trace amounts of immunoglobulin A (IgA) or immunoglobulin M (IgM).2

IVIG is an immunomodulating agent that has multiple activities. These include modulation of complement activation; suppression of idiotypic antibodies; saturation of Fc receptors on macrophages; and suppression of various inflammatory mediators, including cytokines, chemokines, and metalloproteinases.3 The Fc region of IgG facilitates interaction with and signaling through Fc receptors on phagocytes, B cells, and other cells and with Fc-binding plasma proteins (eg, components of the complement system).4

Blockade of macrophage Fc receptors is considered the primary mechanism of action of immune globulin in persons with ITP and other autoantibody-mediated cytopenias. In persons with Kawasaki disease and dermatomyositis, IVIG is thought to inhibit the generation of membrane attack complexes (C5b-C9) and subsequent complement-mediated tissue damage by binding the activated components C3b and C4b, thus preventing their deposition on target surfaces. In persons with dermatomyositis, IVIG induces a decrease in plasma levels of membrane attack complex and a substantial decrease in the amounts of C3b and membrane attack complex deposited in endomysial capillaries. The high content of anti-idiotypes against autoantibodies in IVIG facilitates its ability to neutralize autoantibodies, as is shown in patients with acquired hemophilia due to autoantibodies against factor VIII.4

Specific effects of IVIG have been described. The results of in vitro C3 uptake studies and the effect of IVIG on the clearance of preopsonized cells suggest that IVIG produces a kinetic depression of C3 uptake and modifies the process of complement fragment deposition on erythrocytes.

Normal serum contains IgG, IgM, and IgA antibodies, which are referred to as natural antibodies because they are induced without deliberate immunization and are independent of antigenic exposure. They are considered key to the immunoregulatory effects of immune globulin in immune-mediated disorders.4 Natural autoantibodies appear to be more polyreactive than immune antibodies; natural antibodies can frequently bind to different antigens.4 Natural autoantibodies can (1) bind to pathogens; (2) help remove senescent or altered molecules, cells, and tumors; (3) induce remyelination; and (4) inhibit the growth of autoreactive B-cell clones.

IVIG contains cytokines, antibodies of unclear clinical significance, perhaps neutralizing; interestingly, antibodies against granulocyte macrophage colony-stimulating factor, interferon, interleukin 1, and interleukin 6 in immune globulin have biologic activity in vivo.4 IVIG contains natural antibodies, accounting for some of its effects.

The broad range of applications of IVIG shows the importance of immunoglobulins in the immune homeostasis in healthy people.

A liquid, pasteurized, 10% concentrated intravenous gammaglobulin preparation is as effective as a 5% concentrated preparation.

IVIG replacement prevents severe and lower respiratory tract infections, but not upper respiratory tract and nonrespiratory infections in persons with common variable immune deficiency.5

For excellent patient education resources, visit eMedicine's Cancer and Tumors Center; Skin, Hair, and Nails Center; and Sexually Transmitted Diseases Center. Also, see eMedicine's patient education articles Leukemia, Skin Rashes in Children, and Rapid Oral HIV Test.

Uses of Intravenous Immunoglobulin

IVIG is used to treat a variety of autoimmune, infectious, and idiopathic diseases. IVIG is an approved treatment for graft versus host disease and ITP. It is accepted for use in persons with Kawasaki disease, Guillain-Barré syndrome, and polymyositis/dermatomyositis. The beneficial effects of an intramuscular injection of immune globulin for the prophylactic treatment of patients with primary immunodeficiency syndromes are well established.

The US Food and Drug Administration has approved the use of IVIG for the following 6 conditions:

Its reported uses have been outlined by the National Guideline Clearinghouse, including the following (off-label) applications: 

Additional investigations include the following:

  • Mori (2007) has found that intravenous immunoglobulin therapy does not change the course of Miller Fisher syndrome when used as treatment.6
  • Korber (2007) has reported successful therapy of scleromyxedema with low-dose intravenous immunoglobulin.7
  • Zinman (2007), in a randomized trial of 51 patients with myasthenia gravis, found that IVIG had a positive effect in patients with worsening weakness due to myasthenia gravis.8
  • Suchak (2007)  found that Intravenous immunoglobulin is effective as a sole immunomodulatory agent for treating pyoderma gangrenosum unresponsive to systemic corticosteroids.9  
  • Intravenous immunoglobulins is not recommended as a treatment of atopic dermatitis based on published data.
  • Kerr (2007) has noted type II adult-onset pityriasis rubra pilaris successfully treated with intravenous immunoglobulin.10

Pharmacology and Monitoring

The IVIG that is available contains complete IgG molecules. The IgG subclasses match those in normal human serum. Most preparations contain trace amounts of IgA, which can sensitize IgA-deficient persons during long-term treatment. Immune globulin also contains trace amounts of cytokines, soluble CD4, CD8, and HLA molecules.

Immune globulin is prepared from pooled plasma from 3000-10,000 healthy blood donors. In some instances, blood from as many as 100,000 donors is used. The entire array of variable (antigen-binding) regions of antibodies in normal serum is contained in IVIG. The large number of donors in the pool increases the number of individual antibody activities in the preparation but risks diluting any useful rare activity. Thus, IVIG has the full array of immune antibodies directed compared with nonhost antigens. The large number of donors makes contamination by viruses more possible, but this is rare.

All preparations of IgG have traces of IgA. IgA-deficient patients with severe recurrent viral or bacterial respiratory tract infections or with isolated IgA deficiency (and additional IgG2 and IgG4 deficiency) who may develop severe anaphylactic reactions after an IVIG infusion should receive the first infusion in the hospital under medical supervision.

The following IVIG preparations are marketed in the United States:

  • Gammagard S/D (Baxter/Hyland; Deerfield, Ill)  
    • Lyophilized powder in 5% and 10% concentrations
    • Sodium content in mEq/mL of 0.85%
    • Contains IgM in trace amounts
    • Manufactured by the Cohn-Oncley cold ethanol fractionation process followed by ultrafiltration and ion exchange chromatography; solvent detergent treated; prepared from "a large number of donors"
    • Additives in 5% solution include 0.3% albumin, 2.25% glycine, and 2% glucose
    • pH of 6.8
    • IgA content of 1.6 mcg/mL in 5% solution
  • Gammar-IV (Armour; Blue Bell, Pa)  
    • Lyophilized powder in 5% concentration
    • Sodium content in mEq/mL of 0.5%
    • Prepared by cold alcohol fractionation of pooled plasma; not chemically altered or enzymatically degraded; prepared from a large pool of at least 1000 donors
    • IgA content of less than 25 mcg/mL
  • Gamimune-N (Miles; Elkhart, Ind; Bayer)  
    • Sterile solution in 5% and 10% concentrations
    • Sodium content in mEq/mL considered trace amount (incompatible in saline)
    • Not sugar-glycine based
    • Advanced viral removal and inactivation technologies used in manufacturing; solvent detergent treated
    • Contraindicated in patients with history of prior systemic allergic reaction to IVIG products or a history of IgA deficiency
    • pH of 4-4.5
    • Additives in 5% solution include 9-11% maltose; in 10% solution, 0.16-0.24 M glycine
    • IgA content of 270 mcg/mL
  • Iveegam (Immuno-US; Rochester, NY)  
    • Lyophilized power in 5% concentration
    • Sodium content in mEq/mL of 0.3%
    • Prepared using modified Cohn-fractionation process combined with hydrolase treatment and polyethylene glycol precipitation
    • Additives in 5% solution include 5% glucose and 0.3% NaCl
    • pH of 7.0
    • IgA content of less than 10 mcg/mL
  • Polygam S/D (Baxter/Hyland for American Red Cross; Washington, DC)  
    • Lyophilized powder in 5% and 10% concentrations
    • Sodium content in mEq/mL of 0.85%
    • Manufactured by the Cohn-Oncley cold ethanol fractionation process followed by ultrafiltration and ion exchange chromatography; solvent detergent treated; sterile, freeze-dried preparation of highly purified IgG derived from large pools of human plasma
    • Additives in 5% concentration include 0.3% albumin, 2.25% glycine, and 2% glucose
    • pH of 6.8
    • IgA content less than 1.2 mcg/mL
  • Sandoglobulin (Sandoz; Vienna, Austria)  
    • Lyophilized powder in 3%, 6%, 9%, and 12% concentrations
    • Sterile, highly purified polyvalent antibody product that contains, in concentrated form, all IgG antibodies regularly occurring in donor population
    • Produced by cold alcohol fractionation from the plasma of volunteer US donors; fractionation process includes several filtration steps performed in presence of filter aids; some filtration steps used for separation of cold ethanol precipitate
    • Additives per gram of IgG include 1.67 g sucrose and less than 20 mg NaCl
    • pH of 6.6
    • IgA content of 720 mcg/mL
  • Venoglobulin-I or Venoglobulin-S (Alpha Therapeutic; Los Angeles, Calif)  
    • Sterile solution in 5% and 10% concentrations
    • Sodium content in mEq/mL is less than 1
    • Prepared using cold alcohol fraction, polyethylene glycol bentonite fraction, and ion exchange chromatography; solvent detergent treated
    • Additives in 5% solution include 5% sorbitol and 0.13% albumin; in 10% solution, 5% sorbitol and 0.26% albumin
    • pH of 5.2-5.8
    • IgA content of 15-50 mcg/mL
  • Carimune/Panglobulin (ZLB Bioplasma/ARC Swiss Red Cross)  
    • Lyophilized powder in 3%, 6%, 9%, and 12% concentrations
    • Sodium content in mEq/mL 0-0.9% depending on preparation
    • Viral inactivation and preparation involves Kistler-Nitschmann; cold alcohol fractionation using pH of 4.0, trace pepsin, and nanofiltration
    • pH of Panglobulin is 6.6
    • IgA content of 720 mcg/mL
  • Gamunex (Bayer)  
    • Sterile solution
    • Sodium content in mEq considered trace amount (incompatible in saline)
    • Not sugar-glycine based
    • Viral inactivation and preparation uses pH 4.25, caprylate, ion exchange chromatography, and low salt
    • IgA content of 46 mcg/mL

Baxter AG11 created a new liquid intravenous immunoglobulin product (Immune Globulin Intravenous [IGIV] 10%) using a new manufacturing procedure. Baxter AG used a modified Cohn fractionation and ion exchange chromatography to produce an IgG solution with no alterations to the Fc region. 

KIOVIG™ (Immune Globulin Intravenous [Human]) is one name for this product.  KIOVIG has obtained marketing authorization from the European Medicines Agency (EMEA). KIOVIG is indicated in the European Union for replacement therapy in primary immunodeficiency disorders (PID), myeloma or chronic lymphocytic leukemia (CLL) with severe secondary hypogammaglobulinemia and recurrent infections, children with congenital AIDS and recurrent infections, Kawasaki syndrome, allogeneic bone marrow transplantation, Guillain-Barré Syndrome, and idiopathic thrombocytopenic purpura (ITP) in children or adults at high risk of bleeding or prior to surgery to correct the platelet count.12

Three dedicated virus reduction steps that were included are as follows:

  • Solvent-detergent treatment
  • Nanofiltration
  • Incubation at low pH and elevated temperature in final formulation

Baxter AG's researchers used the reference method of the European Pharmacopoeia (EP) together with a flow-cytometric binding assay for evaluation of the Fc function of the new product. The EP reference method was performed as described in the EP, and the flow-cytometric method was used to measure the binding of IgG to Fc receptors of human monocytic THP-1 cells after exclusion of apoptotic cells. They found that 16 batches of the new product expressed Fc functions between 84% and 110% when analyzed with the EP reference method and Fc-binding activities between 82% and 121% when determined by the flow-cytometric method, making it a very useful form of IVIG.

In late 2006, OMRIX Biopharmaceuticals Inc. was commencing  a United States Phase III open label, single arm, multicenter clinical trial for treatment of primary immune deficiency with Omr-IgG-am™, the Company's IVIG currently marketed outside of the United States. Omr-IgG-am is a highly purified IVIG solution that contains over 95% IgG and only small traces of IgA. The physiological distribution of the IgG subclass is maintained due to a highly effective production process. Two virus removal and/or inactivation steps ensure safety without altering efficiency. Omr-IgG -am does not contain sucrose or albumin. Omr-IgG-am 5% IV is available in 2.5 g (50 mL), 5g (100 mL) and 10 g (200 mL) intravenous solutions and is a ready-to-use liquid preparation that can be stored at room temperature.13

The significance of IgA content in these preparations for patients with IgA deficiency is unclear.

The pharmacokinetic properties of IVIG in healthy persons are well defined and last approximately 22 days; however, in persons with certain illnesses, they can last as few as 6 days.

IVIG therapy should be monitored, and obtaining a history and performing a physical examination, with an emphasis on obtaining information regarding hepatic or kidney disease or a history of reactions to blood products or transfusion reactions, is prudent.

Laboratory tests may include the following:

  • Liver function tests
  • Renal function tests
  • CBC count with differential
  • Hepatitis screen to assess for possible disease transmission by IVIG
  • Immunoglobulin levels to exclude IgA deficiency: If no IgA antibodies are found, then anti-IgA antibody titers should be obtained.
  • Rheumatoid and cryoglobulin levels, because IVIG can cause hematological complications

Finally, store a small amount of serum used before each infusion for analysis in the event of infectious disease transmission.

Intravenous Immunoglobulin and Skin Disease

Because most skin disease has an immunological effect, the fact that IVIG is helpful for treating these conditions is not surprising. It has been reported useful in the treatment of autoimmune blistering diseases, lupus erythematosus, dermatomyositis, scleroderma, toxic epidermal necrolysis, atopic dermatitis, pyoderma gangrenosum, epidermolysis bullosa acquisita, herpes gestationis, erythema multiforme, and chronic autoimmune urticaria. Other uses include treatment for pemphigus foliaceus, mucous membrane pemphigoid, and mixed connective-tissue disease.

IVIG has both agonistic and blocking antibodies against Fas (CD95), the receptor for the Fas ligand, which triggers apoptotic signals into cells. This is what underlies its efficacy for treating toxic epidermal necrolysis.

In persons with dermatomyositis, IVIG decreases plasma levels of membrane attack complex and substantially decreases the amounts of C3b and membrane attack complex deposited in endomysial capillaries.

Idiopathic Thrombocytopenic Purpura

A prime use of IVIG is in the treatment of hematological diseases. The first description of the treatment of individuals with ITP with IVIG was by Imbach et al in 1981.1 They noted that dose administration of IVIG promoted a rapid recovery for children with ITP.

Platelet destruction occurs in the spleen. The spleen contains large numbers of Fc receptor (Fc-gamma-R)–bearing phagocytic cells, such as monocytes and macrophages. These cells can bind and destroy opsonized platelets. Although platelets are destroyed in many different organs, splenectomy is a successful treatment for many cases of ITP. In 1982, Fehr et al demonstrated that in cases of ITP without splenectomy, the infusion of IVIG prolonged the clearance of radiolabeled, antibody-sensitized RBCs in vivo.14

In 1983, Salama et al suggested that the success of IVIG in the treatment of ITP was due to competitive inhibition of Fc receptors on phagocytic cells within the reticuloendothelial system by sensitized erythrocytes.15 Possible mechanisms that underlie this are (1) IVIG dimers and multimers, which are present in low but significant levels in preparations of IVIG, bind to Fc receptors and block platelet clearance and (2) IVIG contains IgG molecules that have a multitude of host antigenic reactivities. These IgG molecules likely bind to host antigens, form immune complexes, and compete with antibody-sensitized platelets for Fc receptors in the reticuloendothelial system, resulting in prolonged platelet survival.16

Other suggested mechanisms for IVIG include the regulatory properties of an antibody type referred to as antiidiotypic antibodies, ie, antibodies that interact with the antigen-combining region of other antibodies. Others have suggested that competitive inhibition by IVIG-induced immune complexes and opsonized platelets for occupancy of activating Fc-gamma-R in the reticuloendothelial system affects the course of ITP. IVIG also has its own immunological effects on the cellular immune response. These involve expression of interleukins and cytokines and growth arrest of lymphocytes.

The standard dose of IVIG is 400 mg/kg daily for 5 days.17,18 A new dosing level is 1 g/kg/d for 2 days, which appears to be more effective.18

Kawasaki Disease and Graft Versus Host Disease

In the United States, the recommended treatment for Kawasaki disease in the acute phase is a single, high dose of intravenous gammaglobulin (2 g/kg) and a high dose of aspirin (80-100 mg/kg/d).

The therapeutic mechanism of IVIG in Kawasaki disease may be partially due to the reversal of the inhibited lymphocyte apoptosis.19 Intravenous gammaglobulin has inhibitory effects on platelet adhesion and thrombus formation. Some competitive inhibition between intact IgG and adhesive protein (eg, von Willebrand factor) is suggested, and Fc receptors of the platelet membrane and Fab and Fc receptors of the subendothelium of the vessel wall may have some role in the interaction. IVIG therapy induces neutrophil apoptosis in persons with Kawasaki disease.

High-dose IVIG down-regulates the activated levels of inflammatory indices (except erythrocyte sedimentation rate) in the acute stage of Kawasaki disease.

IVIG has been shown to decrease the severity of acute graft versus host disease in recipients of allogeneic bone marrow transplants. The dosage is 250 or 500 mg/kg/wk. Prevention against acute graft versus host disease with IVIG might be mediated by the induction of apoptosis of activated alloreactive CD4+ CD134+ donor T cells.20

Other Uses

  • The effectiveness of IVIG as a treatment for recurrent spontaneous pregnancy loss remains unproven. IVIG does not prevent further losses among women with primary, recurrent, spontaneous pregnancy loss.
  • One study suggests that IVIGs are effective in the treatment of pretibial myxedema and may have immunomodulatory action in patients with Graves disease and related disorders.
  • Patients with ataxic sensory neuronopathy with Sjögren syndrome and stiff man syndrome have benefited from IVIG therapy.
  • Selected patients with chronic lymphocytic leukemia who are at risk of bacterial infection can be substantially protected from this complication by regular therapy with IVIG.
  • Chronic idiopathic pericarditis is a chronic disease of unknown origin characterized by recurrent episodes of pericardial inflammation. The cause of the recurrence is unknown, although in some cases it may be traced to a viral infection and to the presence of antimyocardial antibodies. Because a viral infection can induce an autoimmune process through a mechanism of molecular mimicry and because the optimal therapy to prevent recurrences has not been established, Peterlana et al reasoned that treatment with human IVIG could be beneficial for patients who did not respond to previous immunosuppressive therapies. Four patients affected by chronic idiopathic pericarditis benefited from 5 treatments of monthly high-dose human IVIG (0.4 g/kg/d for 5 d) followed by administration every 2 months. Three of 4 patients could permanently discontinue steroid therapy and were still in remission after years of follow-up.21
  • The beneficial effects on cardiac function from IVIG treatment in patients with dilated cardiomyopathy is not due to neutralization of antireceptor autoantibody.22
  • IVIG and interferon have been reported as a successful treatment for optic neuritis in patients with pediatric multiple sclerosis.
  • Successful management of cataplexy with IVIGs at narcolepsy onset has been reported.23
  • IVIG therapy reportedly has been successful in the treatment of acute disseminated encephalomyelitis.
  • IVIG therapy for Alzheimer disease has had mixed success.
  • Patients with Churg-Strauss syndrome have achieved complete clinical and functional recovery with a long-term stable remission with IVIG therapy and plasmapheresis, and the incidence of adverse effects was low.24
  • IVIG treatment for the first year from onset of the first neurological event suggestive of demyelinative disease significantly lowers the incidence of a second attack and reduces disease activity as measured by brain magnetic resonance imaging.25
  • IVIG was well tolerated and therapy was completed in 9 patients with livedoid vasculitis who were treated with IVIG. In all patients, the clinical evaluation revealed a marked improvement of erythema, pain, and healing of areas of active ulceration. Although this was an open noncontrolled study, the authors propose that IVIG is a promising therapeutic option for livedoid vasculitis refractory to other treatment modalities.26

Adverse Effects

Undesirable effects from IVIG occur in less than 5% of patients. The most common adverse effects occur soon after infusions and can include headache, flushing, chills, myalgia, wheezing, tachycardia, lower back pain, nausea, and hypotension. If this happens during an infusion, the infusion should be slowed or stopped. If symptoms are anticipated, a patient can be premedicated with antihistamines and intravenous hydrocortisone.

  • IVIG can induce reactions in patients with IgA deficiency. This occurs in 1 in 500-1000 patients. Serious anaphylactoid reactions occur soon after the administration of IVIG. Anaphylaxis associated with sensitization to IgA in patients with IgA deficiency can be prevented by using IgA-depleted immune globulin. The presence of IgG anti-IgA antibodies is not always associated with severe adverse reactions to IVIG.4
  • An uncommon but potentially irreversible adverse event is acute renal failure. From June 1985 to November 1998, the US Food and Drug Administration received 120 reports worldwide, 88 in the United States, of renal injury. Acute renal failure with IVIG therapy occurs with the sucrose-stabilized formulation, but not with the D-sorbitol–stabilized formulation.
  • IVIG is associated with rare cases of thrombosis. It has caused disseminated intravascular coagulation, transient serum sickness, and transient neutropenia.
  • One study reported 7 patients who had thromboembolic events while being treated with IVIG.27 Four patients had strokes or transient ischemic attacks, 1 had an inferior wall myocardial infarction, 1 developed deep venous thrombosis, and 1 had a retinal artery infarct. The age range of the patients was 57-81 years, and most had underlying risk factors such as hypertension, hypercholesterolemia, atrial fibrillation, history of vascular disease and stroke, and deep venous thrombosis. Three patients received multiple IVIG infusions before developing the thromboembolic complications. Therefore, clinicians should be vigilant about the possibility of thromboembolic complications with each IVIG infusion and should be especially judicious with the use of IVIG in patients with underlying risk factors.
  • Life-threatening human parvovirus B19 infection and hepatitis C have been transmitted by IVIG.
  • Severe cutaneous vasculitis has been reported following an intravenous infusion of gammaglobulin in a patient with type II mixed cryoglobulinemia.
  • IVIG can precipitate acute myocardial infarction.
  • Aseptic meningitis is a rare but well-recognized complication of IVIG therapy. It manifests as fever, neck stiffness, headache, confusion, nausea, and vomiting.
  • IVIG therapy can result in postinfusion hyperproteinemia, increased serum viscosity, and pseudohyponatremia.
  • IVIG should not be given to patients with sensitivity to thimerosal.
  • IVIG has caused eczematous dermatitis and alopecia.
  • Complement consumption associated with an eczematous cutaneous reaction has been noted during infusions of high doses of IVIG.
  • Orbach et al noted encouraging reports on the efficacy of IVIG in different types of glomerulonephritis (mainly lupus nephritis) resistant to conventional therapy, but the exact success rate and clinical indications remain undetermined. However, the issue of IVIG treatment and renal function is a 2-edged sword because nephrotoxicity can be a serious rare complication of IVIG therapy. Products containing sucrose as a stabilizer are mainly associated with such injury through the mechanism of osmotic nephrosis. Preexisting renal disease, volume depletion, and old age are risk factors for such toxicity.28
  • Cedars Sinai Medical Center developed a protocol using high-dose (2 mg/kg) IVIG to desensitize transplantation patients who are broadly sensitized to HLA antigens.
    • Since 2000, 57 broadly sensitized patients (19 with cadaver donor kidneys and 38 with living donor kidneys) have been evaluated and subsequently undergone transplantation following IVIG treatment. The incidence of allograft rejection was 38.5%, and 4-year patient and graft survival rates were 96.5% and 82.5%, respectively.
    • IVIG has also been used in combination with pulse steroids to treat antibody-mediated rejection episodes in 18 patients with C4d deposition in rejection biopsy specimens. Thirteen responded to treatment and 5 grafts were lost in this group with severe antibody-mediated rejections.
    • These results suggest that in many cases, high-dose IVIG treatment can neutralize or mitigate antibody responses to eliminate positive donor-specific crossmatches and permit transplantation of broadly sensitized patients, and they suggest a means to successfully treat antibody-mediated rejection.29

Keywords

intravenous immunoglobulin, IVIG, gamma globulin, gammaglobulin, intravenous Ig, immunoglobulin preparations, Ig preparations, immunomodulating agents, idiopathic thrombocytopenic purpura, ITP, Kawasaki disease, Kawasaki's disease, graft versus host disease, GVHD, graft vs host disease, graft-vs-host disease, graft-versus-host disease, Guillain-Barré syndrome, Guillain-Barre syndrome, polymyositis/dermatomyositis, polymyositis, dermatomyositis, blood disease, hematological disease, hematologic disease,immune dysfunction

 


More on Intravenous Immunoglobulin

References
[ CLOSE WINDOW ]

References

  1. Imbach P, Barandun S, dApuzzo V, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet. Jun 6 1981;1(8232):1228-31. [Medline].

  2. Rutter A, Luger TA. High-dose intravenous immunoglobulins: an approach to treat severe immune-mediated and autoimmune diseases of the skin. J Am Acad Dermatol. Jun 2001;44(6):1010-24. [Medline].

  3. Dalakas MC. Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. Neurology. Dec 24 2002;59(12 Suppl 6):S13-21. [Medline].

  4. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med. Sep 6 2001;345(10):747-55. [Medline].

  5. Favre O, Leimgruber A, Nicole A, Spertini F. Intravenous immunoglobulin replacement prevents severe and lower respiratory tract infections, but not upper respiratory tract and non-respiratory infections in common variable immune deficiency. Allergy. Mar 2005;60(3):385-90. [Medline].

  6. Mori M, Kuwabara S, Fukutake T, Hattori T. Intravenous immunoglobulin therapy for Miller Fisher syndrome. Neurology. Apr 3 2007;68(14):1144-6. [Medline].

  7. Körber A, Franckson T, Grabbe S, Dissemond J. Successful therapy of scleromyxoedema Arndt-Gottron with low-dose intravenous immunoglobulin. J Eur Acad Dermatol Venereol. Apr 2007;21(4):553-4. [Medline].

  8. [Best Evidence] Zinman L, Ng E, Bril V. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology. Mar 13 2007;68(11):837-41. [Medline].

  9. Suchak R, Macedo C, Glover M, Lawlor F. Intravenous immunoglobulin is effective as a sole immunomodulatory agent in pyoderma gangrenosum unresponsive to systemic corticosteroids. Clin Exp Dermatol. Mar 2007;32(2):205-7. [Medline].

  10. Kerr AC, Ferguson J. Type II adult-onset pityriasis rubra pilaris successfully treated with intravenous immunoglobulin. Br J Dermatol. May 2007;156(5):1055-6. [Medline].

  11. Reipert BM, Ilas J, Carnewal C, Füreder SF, Bölzlbauer U, Teschner W. Fc function of a new intravenous immunoglobulin product: IGIV 10% triple virally inactivated solution. Vox Sang. Oct 2006;91(3):256-63. [Medline].

  12. Baxter Receives Marketing Authorization from the European Commission for KIOVIG to Treat Immunodeficiencies. Available at http://www.baxter.com/about_baxter/news_room/news_releases/2006/01-25-06-kiovig.html. Accessed November 3, 2007.

  13. OMRIX Biopharmaceuticals Inc. OMRIX Biopharmaceuticals Announces U.S. Phase III Clinical Trial for Intravenous Immunoglobulin (IVIG) in Subjects with Primary Immune Deficiency Diseases. Available at http://www.pipelinereview.com/joomla/content/view/5935/102/. Accessed November 3, 2007.

  14. Fehr J, Hofmann V, Kappeler U. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin. N Engl J Med. May 27 1982;306(21):1254-8. [Medline].

  15. Salama A, Mueller-Eckhardt C, Kiefel V. Effect of intravenous immunoglobulin in immune thrombocytopenia. Lancet. Jul 23 1983;2(8343):193-5. [Medline].

  16. Lazarus AH, Crow AR. Mechanism of action of IVIG and anti-D in ITP. Transfus Apheresis Sci. Jun 2003;28(3):249-55. [Medline].

  17. Chandramouli NB, Rodgers GM. Prolonged immunoglobulin and platelet infusion for treatment of immune thrombocytopenia. Am J Hematol. Sep 2000;65(1):85-6. [Medline]. [Full Text].

  18. Laosombat V, Wiriyasateinkul A, Wongchanchailert M. Intravenous gamma globulin for treatment of chronic idiopathic thrombocytopenic purpura in children. J Med Assoc Thai. Feb 2000;83(2):160-8. [Medline].

  19. Yi QJ, Li CR, Yang XQ. Effect of intravenous immunoglobulin on inhibiting peripheral blood lymphocyte apoptosis in acute Kawasaki disease. Acta Paediatr. Jun 2001;90(6):623-7. [Medline].

  20. Caccavelli L, Field AC, Betin V, et al. Normal IgG protects against acute graft-versus-host disease by targeting CD4(+)CD134(+) donor alloreactive T cells. Eur J Immunol. Sep 2001;31(9):2781-90. [Medline].

  21. Peterlana D, Puccetti A, Simeoni S, et al. Efficacy of intravenous immunoglobulin in chronic idiopathic pericarditis: report of four cases. Clin Rheumatol. Feb 2005;24(1):18-21. [Medline].

  22. Larsson L, Mobini R, Aukrust P, et al. Beneficial effect on cardiac function by intravenous immunoglobulin treatment in patients with dilated cardiomyopathy is not due to neutralization of anti-receptor autoantibody. Autoimmunity. Sep-Nov 2004;37(6-7):489-93. [Medline].

  23. Dauvilliers Y, Carlander B, Rivier F, et al. Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset. Ann Neurol. Dec 2004;56(6):905-8. [Medline].

  24. Danieli MG, Cappelli M, Malcangi G, et al. Long term effectiveness of intravenous immunoglobulin in Churg-Strauss syndrome. Ann Rheum Dis. Dec 2004;63(12):1649-54. [Medline].

  25. Achiron A, Kishner I, Sarova-Pinhas I, et al. Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial. Arch Neurol. Oct 2004;61(10):1515-20. [Medline].

  26. Kreuter A, Gambichler T, Breuckmann F, et al. Pulsed intravenous immunoglobulin therapy in livedoid vasculitis: an open trial evaluating 9 consecutive patients. J Am Acad Dermatol. Oct 2004;51(4):574-9. [Medline].

  27. Vucic S, Chong PS, Dawson KT, et al. Thromboembolic complications of intravenous immunoglobulin treatment. Eur Neurol. 2004;52(3):141-4. [Medline].

  28. Orbach H, Tishler M, Shoenfeld Y. Intravenous immunoglobulin and the kidney--a two-edged sword. Semin Arthritis Rheum. Dec 2004;34(3):593-601. [Medline].

  29. Jordan SC, Vo AA, Nast CC, Tyan D. Use of high-dose human intravenous immunoglobulin therapy in sensitized patients awaiting transplantation: the Cedars-Sinai experience. Clin Transpl. 2003;193-8. [Medline].

  30. Adrogue HE, Soltero L, Land GA, Ramanathan V, Truong LD, Suki WN. Immunoglobulin therapy for plasma cell-rich rejection in the renal allograft. Transplantation. Aug 27 2006;82(4):567-9. [Medline].

  31. Chapman SA, Gilkerson KL, Davin TD, Pritzker MR. Acute renal failure and intravenous immune globulin: occurs with sucrose-stabilized, but not with D-sorbitol-stabilized, formulation. Ann Pharmacother. Dec 2004;38(12):2059-67. [Medline].

  32. Cordonnier C, Chevret S, Legrand M, et al. Should immunoglobulin therapy be used in allogeneic stem-cell transplantation? A randomized, double-blind, dose effect, placebo-controlled, multicenter trial. Ann Intern Med. Jul 1 2003;139(1):8-18. [Medline].

  33. Herzog-Tzarfati K, Shiloah E, Koren-Michowitz M, Minha S, Rapoport MJ. Successful treatment of prolonged agranulocytosis caused by acute parvovirus B19 infection with intravenous immunoglobulins. Eur J Intern Med. Oct 2006;17(6):439-40. [Medline].

  34. Hommes OR, Sorensen PS, Fazekas F, et al. Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. Lancet. Sep 25 2004;364(9440):1149-56. [Medline].

  35. Lee KY, Lee HS, Hong JH, et al. High-dose Intravenous Immunoglobulin Downregulates the Activated Levels of Inflammatory Indices Except Erythrocyte Sedimentation Rate in Acute Stage of Kawasaki Disease. J Trop Pediatr. Jan 26 2005;[Medline].

  36. Marie I, Maurey G, Hervé F, Hellot MF, Levesque H. Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature. Br J Dermatol. Oct 2006;155(4):714-21. [Medline].

  37. Masterson R, Pellicano R, Bleasel K, McMahon LP. Wegener's granulomatosis in pregnancy: a novel approach to management. Am J Kidney Dis. Oct 2004;44(4):e68-72. [Medline].

  38. Matamoros N, De Gracia J, Hernandez F, et al. A prospective controlled crossover trial of a new presentation (10% vs. 5%) of a heat-treated intravenous immunoglobulin. Int Immunopharmacol. Mar 2005;5(3):619-26. [Medline].

  39. National Guideline Clearinghouse, University HealthSystem Consortium, Technology Assessment Program of the Clinical Practice Advancement Center. Technology assessment: intravenous immunoglobulin preparations. Oak Brook, Ill: University HealthSystem Consortium;. Mar 1999;216 pages. [Full Text].

  40. National Institutes of Health. Intravenous Immunoglobulin: Prevention and Treatment of Disease. Available at: http://consensus.nih.gov/cons/080/080_statement.htm. Bethesda, Md: National Institutes of Health; May 21-23, 1990. [Full Text].

  41. Sandler SG, Tutuncuoglu SO. Immune thrombocytopenic purpura - current management practices. Expert Opin Pharmacother. Dec 2004;5(12):2515-27. [Medline].

  42. Sokos DR, Berger M, Lazarus HM. Intravenous immunoglobulin: appropriate indications and uses in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2002;8(3):117-30. [Medline].

  43. Spalice A, Properzi E, Lo Faro V, Acampora B, Iannetti P. Intravenous immunoglobulin and interferon: successful treatment of optic neuritis in pediatric multiple sclerosis. J Child Neurol. Aug 2004;19(8):623-6. [Medline].

[ CLOSE WINDOW ]

Further Reading

[ CLOSE WINDOW ]

Keywords

intravenous immunoglobulin, IVIG, gamma globulin, gammaglobulin, intravenous Ig, immunoglobulin preparations, Ig preparations, immunomodulating agents, idiopathic thrombocytopenic purpura, ITP, Kawasaki disease, Kawasaki's disease, graft versus host disease, GVHD, graft vs host disease, graft-vs-host disease, graft-versus-host disease, Guillain-Barré syndrome, Guillain-Barre syndrome, polymyositis/dermatomyositis, polymyositis, dermatomyositis, blood disease, hematological disease, hematologic disease,immune dysfunction

[ CLOSE WINDOW ]

Contributor Information and Disclosures

Author

Noah S Scheinfeld, MD, JD, FAAD, Assistant Clinical Professor, Department of Dermatology, Columbia University; Consulting Staff, Department of Dermatology, St Luke's Roosevelt Hospital Center, Beth Israel Medical Center, New York Eye and Ear Infirmary; Private Practice
Noah S Scheinfeld, MD, JD, FAAD is a member of the following medical societies: American Academy of Dermatology
Disclosure: Optigenex Consulting fee Independent contractor

Coauthor(s)

John E Godwin, MD, MS, Professor of Medicine, Chief Division of Hematology/Oncology, Associate Director, Simmons Cooper Cancer Institute, Southern Illinois University School of Medicine
John E Godwin, MD, MS is a member of the following medical societies: American Association for the Advancement of Science, American Heart Association, and American Society of Hematology
Disclosure: Nothing to disclose.

Medical Editor

S Gerald Sandler, MD, FACP, FCAP, Professor of Medicine and Pathology; Director, Transfusion Medicine, Department of Laboratory Medicine, Georgetown University Hospital
S Gerald Sandler, MD, FACP, FCAP is a member of the following medical societies: American Association of Blood Banks, College of American Pathologists, International Society of Blood Transfusions, and Medical Society of the District of Columbia
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Troy H Guthrie, Jr, MD, Director of Cancer Institute, Baptist Medical Center
Troy H Guthrie, Jr, MD is a member of the following medical societies: American Federation for Medical Research, American Medical Association, American Society of Hematology, Florida Medical Association, Medical Association of Georgia, and Southern Medical Association
Disclosure: Nothing to disclose.

CME Editor

Rajalaxmi McKenna, MD, FACP, Consulting Staff, Department of Medicine, Southwest Medical Consultants, SC, Good Samaritan Hospital, Advocate Health Systems
Rajalaxmi McKenna, MD, FACP is a member of the following medical societies: American Society of Clinical Oncology, American Society of Hematology, and International Society on Thrombosis and Haemostasis
Disclosure: Nothing to disclose.

Chief Editor

Emmanuel C Besa, MD, Professor, Department of Medicine, Division of Hematologic Malignancies, Kimmel Cancer Center, Thomas Jefferson University
Emmanuel C Besa, MD is a member of the following medical societies: American Association for Cancer Education, American College of Clinical Pharmacology, American Federation for Medical Research, American Society of Hematology, and New York Academy of Sciences
Disclosure: Nothing to disclose.

RELATED INFORMATION FROM INDUSTRY
 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.